Response to the combination of cetuximab, bevacizumab and irinotecan (cetux/bev/iri) in patients (pts) previously treated with 3rd-line panitumumab, following disease progression on oxaliplatin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results